Are you a quality manager for a small medical device start-up looking to expand into global markets? Or maybe you are a seasoned device manufacturer preparing to once again traverse quality regulations to deliver a new product to the European market?

Six years after the referendum we can disentangle the evidence and judge the effects on health and care, says Richard Vize.

NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage.

US, European, Japanese and Chinese patients could get novel medicines ahead of patients in the UK after Brexit, the CEO of French pharma Ipsen has said in an interview.